Cost-Effectiveness of Clopidogrel plus Aspirin versus Aspirin Alone for Secondary Prevention of Cardiovascular Events: Results from the CHARISMA Trial

This publication has 28 references indexed in Scilit:

• Patients With Prior Myocardial Infarction, Stroke, or Symptomatic Peripheral Arterial Disease in the CHARISMA Trial
  Journal of the American College of Cardiology, 2007
• Clopidogrel and Aspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events
  New England Journal of Medicine, 2006
• International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis
  JAMA, 2006
• Estimating Survival for Cost-Effectiveness Analyses: A Case Study in Atherothrombosis
  Value in Health, 2004
• Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial
  American Heart Journal, 2004
• Early and Sustained Dual Oral Antiplatelet Therapy Following Percutaneous Coronary Intervention
  JAMA, 2002
• Cost and Cost-effectiveness of an Early Invasive vs Conservative Strategy for the Treatment of Unstable Angina and Non–ST-Segment Elevation Myocardial Infarction
  JAMA, 2002
• Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation
  New England Journal of Medicine, 2001
• Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study
  The Lancet, 2001
• Health Databases in Saskatchewan
  Published by Wiley ,2000